全文获取类型
收费全文 | 5111篇 |
免费 | 422篇 |
国内免费 | 85篇 |
专业分类
耳鼻咽喉 | 79篇 |
儿科学 | 142篇 |
妇产科学 | 34篇 |
基础医学 | 366篇 |
口腔科学 | 45篇 |
临床医学 | 567篇 |
内科学 | 1385篇 |
皮肤病学 | 51篇 |
神经病学 | 365篇 |
特种医学 | 76篇 |
外科学 | 294篇 |
综合类 | 767篇 |
预防医学 | 109篇 |
眼科学 | 46篇 |
药学 | 241篇 |
中国医学 | 665篇 |
肿瘤学 | 386篇 |
出版年
2024年 | 3篇 |
2023年 | 73篇 |
2022年 | 108篇 |
2021年 | 199篇 |
2020年 | 222篇 |
2019年 | 138篇 |
2018年 | 168篇 |
2017年 | 170篇 |
2016年 | 174篇 |
2015年 | 182篇 |
2014年 | 321篇 |
2013年 | 394篇 |
2012年 | 284篇 |
2011年 | 417篇 |
2010年 | 268篇 |
2009年 | 244篇 |
2008年 | 269篇 |
2007年 | 266篇 |
2006年 | 239篇 |
2005年 | 225篇 |
2004年 | 157篇 |
2003年 | 158篇 |
2002年 | 132篇 |
2001年 | 116篇 |
2000年 | 75篇 |
1999年 | 78篇 |
1998年 | 69篇 |
1997年 | 43篇 |
1996年 | 41篇 |
1995年 | 61篇 |
1994年 | 42篇 |
1993年 | 37篇 |
1992年 | 27篇 |
1991年 | 20篇 |
1990年 | 21篇 |
1989年 | 16篇 |
1988年 | 22篇 |
1987年 | 14篇 |
1986年 | 13篇 |
1985年 | 23篇 |
1984年 | 16篇 |
1983年 | 11篇 |
1982年 | 10篇 |
1981年 | 7篇 |
1980年 | 13篇 |
1979年 | 13篇 |
1978年 | 6篇 |
1977年 | 2篇 |
1976年 | 5篇 |
1973年 | 3篇 |
排序方式: 共有5618条查询结果,搜索用时 15 毫秒
1.
2.
3.
《Transfusion and apheresis science》2022,61(4):103421
BackgroundTherapeutic plasma exchange (TPE) is an extracorporeal treatment that can be used in adult and pediatric patients with acute demyelinating syndromes of the central nervous system. In this study, the efficacy and safety of TPE was evaluated in 10 pediatric patients who underwent TPE that were unresponsive to corticosteroid treatment.MethodsRecords of 10 pediatric patients who underwent TPE in our pediatric intensive care unit (PICU) between May 2017 and June 2020 were used. Expanded Disability Status Scale (EDSS), Gait Scale (GS), and Visual Outcome Scale (VOS) were applied to the patients before and after TPE.ResultsOf the 10 patients who underwent TPE, five were diagnosed with multiple sclerosis (MS), three with transverse myelitis (TM), and two with acute disseminated encephalomyelitis (ADEM). The median age of the patients was 13.3 years (IQR 8-15), and the median day from symptom onset to onset of TPE was 12.5 days (IQR 7-28). A total of 104 TPE sessions were performed successfully. While no complications were encountered in three patients during the sessions, the most common complication was hypofibrinogenemia. The decrease in EDSS and GS scores was found to be consistent with the clinical response of the patients. There was no statistically significant decrease in the VOS.ConclusionsWith this study, we can say that TPE is a feasible, effective, and safe treatment modality in children with acute demyelinating syndromes of the central nervous system. 相似文献
4.
目的 探讨预激综合征伴心房颤动射频消融术后心房颤动的复发率,为临床预防和干预提供理论依据。方法 计算机检索 PubMed、Web of Science、The Cochrane Library、Embase、CNKI、WanFang Data、CBM及VIP数据库,搜索建库至2022年3月26日与预激综合征伴心房颤动患者行射频消融术治疗后心房颤动复发率相关的研究。由2名研究员独立筛选文献、提取资料并文献质量评价,采用R 4.1.0软件进行meta分析。结果 纳入14篇研究,共计851例患者,meta分析结果显示预激综合征伴心房颤动射频消融术后心房颤动的总复发率为0.13(95%CI:0.08~0.19,P<0.01)。其中,亚组分析显示:单纯房室旁道消融术和房室旁道消融联合肺静脉隔离术复发率分别为:0.15(95%CI:0.09~0.21,P<0.01)和0.07(95%CI:0.01~0.15,P<0.01);单旁道和多旁道复发率分别为0.19(95%CI:0.12~0.28,P=0.01)和0.05(95%CI:0.00~0.20,P=0.10);左侧和右侧旁道复发率分别为0.14(95%CI:0.07~0.21,P<0.01)和0.10(95%CI:0.06~0.16,P=0.07);年龄≤40岁和>40岁复发率分别为0.10(95%CI:0.01~0.23,P<0.01)和0.15(95%CI:0.09~0.21,P<0.01);随访时间≤1年和>1年复发率分别为0.08(95%CI:0.02~0.17,P=0.09)和0.17(95%CI:0.14~0.21,P=0.17);样本量≤50例和>50例复发率分别为0.18(95%CI:0.09~0.29,P<0.01)和0.11(95%CI:0.06~0.17,P<0.01);男性和女性复发率分别为0.10(95%CI:0.04~0.19,P<0.01)和0.19(95%CI:0.12~0.28,P=0.26);合并器质性心脏病和不合并复发率分别为0.34(95%CI:0.15~0.57,P<0.01)和0.04(95%CI:0.00~0.10,P<0.01)。结论 当前证据表明,预激综合征伴心房颤动射频消融术后心房颤动的复发率较高,相对于单纯房室旁道消融,旁道消融联合肺静脉隔离降低复发率效果更优,年龄及随访时间与复发率呈正相关。 相似文献
5.
6.
《Journal of Cardiovascular Computed Tomography》2022,16(1):54-122
AimThis clinical practice guideline for the evaluation and diagnosis of chest pain provides recommendations and algorithms for clinicians to assess and diagnose chest pain in adult patients.MethodsA comprehensive literature search was conducted from November 11, 2017, to May 1, 2020, encompassing randomized and nonrandomized trials, observational studies, registries, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, Agency for Healthcare Research and Quality reports, and other relevant databases. Additional relevant studies, published through April 2021, were also considered.StructureChest pain is a frequent cause for emergency department visits in the United States. The “2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain” provides recommendations based on contemporary evidence on the assessment and evaluation of chest pain. This guideline presents an evidence-based approach to risk stratification and the diagnostic workup for the evaluation of chest pain. Cost-value considerations in diagnostic testing have been incorporated, and shared decision-making with patients is recommended. 相似文献
7.
Brittany C. McGill PhD MPsych Claire E. Wakefield PhD MPH Katherine M. Tucker MD Rebecca A. Daly MAP Mark W. Donoghoe PhD Janine Vetsch PhD Meera Warby MGC Noemi A. Fuentes-Bolanos MD PhD Kristine Barlow-Stewart PhD Judy Kirk MD Eliza Courtney MGC Tracey A. O’Brien MD MBA MHL Glenn M. Marshall MD Mark Pinese PhD Mark J. Cowley PhD Vanessa Tyrrell BAppSc MBA FHGSA ARCPA Rebecca J. Deyell MD MHSc David S. Ziegler MBBS MD Kate Hetherington MPsych PhD 《Cancer》2023,129(22):3620-3632
Background
Germline genome sequencing in childhood cancer precision medicine trials may reveal pathogenic or likely pathogenic variants in cancer predisposition genes in more than 10% of children. These findings can have implications for diagnosis, treatment, and the child’s and family’s future cancer risk. Understanding parents’ perspectives of germline genome sequencing is critical to successful clinical implementation.Methods
A total of 182 parents of 144 children (<18 years of age) with poor-prognosis cancers enrolled in the Precision Medicine for Children with Cancer trial completed a questionnaire at enrollment and after the return of their child’s results, including clinically relevant germline findings (received by 13% of parents). Parents’ expectations of germline genome sequencing, return of results preferences, and recall of results received were assessed. Forty-five parents (of 43 children) were interviewed in depth.Results
At trial enrollment, most parents (63%) believed it was at least “somewhat likely” that their child would receive a clinically relevant germline finding. Almost all expressed a preference to receive a broad range of germline genomic findings, including variants of uncertain significance (88%). Some (29%) inaccurately recalled receiving a clinically relevant germline finding. Qualitatively, parents expressed confusion and uncertainty after the return of their child’s genome sequencing results by their child’s clinician.Conclusions
Many parents of children with poor-prognosis childhood cancer enrolled in a precision medicine trial expect their child may have an underlying cancer predisposition syndrome. They wish to receive a wide scope of information from germline genome sequencing but may feel confused by the reporting of trial results. 相似文献8.
BackgroundRestricted shoulder fascia displacement may be an etiological factor for myofascial pain syndrome. A diagnostic ultrasound video can follow deep fascia displacement during active cervical movements. Trackers can be applied to videos to convert deep fascia displacement into data points. This study reports on assessors' reliability in evaluating direction and quantifying upper trapezius' deep fascia displacement during active cervical movements.MethodsPT-Sonographer 1 recorded deep fascia displacement of upper trapezius for three sets using HS1 Konica Minolta diagnostic ultrasound. The recording sequence used was cervical flexion, extension, right lateral flexion, left lateral flexion, right rotation, and left rotation. The three assessors used the tracker to determine direction of deep fascia displacement. PT-Sonographer 1 used the tracker three times in quantifying deep fascia displacement. Intraclass correlation coefficient and Kappa determined the assessors' intra-tester and inter-tester reliability.ResultsTen participants were included in the study with a mean±(SD) age of 37±(6). All the assessors had acceptable intra-tester reliability in determining deep fascia displacement on tracker (ICC≥0.40). All assessors had clinically unacceptable inter-tester reliability in determining deep fascia displacement when tracking right rotation (ICC < 0.40). PT-Sonographer 1 had clinically unacceptable intra-tester reliability in determining deep fascia displacement when tracking left rotation (ICC<0.40).ConclusionWe report clinically acceptable assessors' reliability in determining direction and total deep fascia displacement when tracking diagnostic ultrasound videos of cervical flexion, extension, and lateral flexion. Checking for reliable deep fascia displacements may distinguish MPS from non-MPS individuals increasing the utility of diagnostic ultrasound machine and tracker in clinical practice. 相似文献
9.
Joo-Hee Kim Jae-Hyuk Jang So-Hee Lee Eun-Mi Yang Seung Hun Jang Ki-Suck Jung Hae-Sim Park 《Allergy, asthma & immunology research》2021,13(2):271
PurposeSpecific antibody deficiency (SAD) involves a deficient response to a polysaccharide vaccine despite having normal immunoglobulin levels. The failure of the polysaccharide response can be observed as a component of various primary antibody deficiencies. However, only a few studies have described the clinical and immunological profiles in SAD and/or other primary immunodeficiencies (PIDs) in adults.MethodsA total of 47 patients who had a clinical history suggestive of antibody deficiency or had already been diagnosed with various antibody deficiencies were enrolled. Polysaccharide responses to 7 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) were measured using the World Health Organization enzyme-linked immunosorbent assay (WHO-ELISA), and postvaccination immunoglobulin G (IgG) titers were compared to clinical and laboratory parameters.ResultsBased on the American Academy of Allergy, Asthma, and Immunology (AAAAI) criteria for the WHO-ELISA, 11 (23.4%) patients were diagnosed as having SAD. Sixteen-three percent of them had combined with other types of PID, such as IgG subclass deficiency and hypogammaglobulinemia. Postvaccination IgG titers for the serotypes 4/9V/18C correlated with IgG2 (P = 0.012, P = 0.001, and P = 0.004) and for 6B/9V/14 with IgG3 (P = 0.003, P = 0.041, and P = 0.036, respectively). The IgG3 subclass levels negatively correlated with forced expiratory volume in 1 second (FEV1, %) and FEV1/forced vital capacity (P < 0.001 and P = 0.001, respectively).ConclusionSAD can be diagnosed in patients with normal IgG levels as well as in those deficient in IgG or the IgG3 subclass, implicating that restricted responses to Streptococcus pneumoniae polysaccharide antigens commonly exist in patients with predominantly antibody deficiency. 相似文献
10.
《Journal of thoracic oncology》2021,16(3):381-394
Immune checkpoint inhibitors (ICIs) have transformed the prognosis of cancers previously considered lethal. The spectrum of therapeutic indications is rapidly expanding, including the vast majority of thoracic malignancies. By enhancing the immune responses against cancer, the ICI treatments lead to the development of immune-related adverse events (irAEs) that may affect any organ. Severity varies from mild to fatal clinical manifestations. Neurologic involvement is relatively rare and highly heterogeneous, including central and peripheral nervous system diseases associated with neural-specific autoantibodies or not, central nervous system vasculitis, and granulomatous and demyelinating disorders. Symptoms often manifest within the first four cycles of treatment and can develop regardless of the class of ICI used. An unfavorable outcome is found in up to one-third of patients and is generally associated with the patients’ clinical characteristics (e.g., age, coexistence of systemic adverse events), cancer type (e.g., lung cancer versus other), and specific clinical setting (e.g., ICI treatment in patients with preexisting paraneoplastic neurologic autoimmunity, ICI rechallenge after a first neurologic irAE). Diagnosis should be suspected in patients with new-onset neurologic symptoms while on ICI treatment which are not explained by metastatic disease or other metabolic/infectious disorders. Recommended treatment is based on clinical severity and consists of ICI discontinuation with or without immunosuppressive/immunomodulatory therapy, although alternative approaches are reasonable depending on cancer status (e.g., aggressive immunosuppression without discontinuing ICI in patients with initial cancer response). Early recognition and appropriate treatment of these neurologic irAEs are crucial for improved patient outcomes and therapeutic planning. 相似文献